Bruno Lins de Souza

Bruno Lins de Souza

Auto-generated profile, based on publicly available information

Bruno Lins de Souza

Department of Medicine Federal University of Ceará Fortaleza Ceará Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2026 in Acta Diabetologica
Verified
Journal Article
Closed access
NGNaveen Gautam
Naveen Gautam
BSBruno Lins de Souza
Bruno Lins de Souza
JAJessica Abramowitz
Jessica Abramowitz
DMDenise Machado Mourão
Denise Machado Mourão
SMSasan Mirfakhraee
Sasan Mirfakhraee
MAMarconi Abreu
Marconi Abreu

1 July 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
TCThomaz Alexandre Costa
Thomaz Alexandre Costa
GCGabriel Cavalcante Lima Chagas
Gabriel Cavalcante Lima Chagas
LSLuma Maria Tavares de Sousa
Luma Maria Tavares de Sousa
BSBruno Lins de Souza
Bruno Lins de Souza
NFNicole Felix
Nicole Felix
BLBruno Bezerra Lima
Bruno Bezerra Lima
Background: Left ventricular (LV) thrombus is a complication of myocardial infarction and dilated cardiomyopathy and is associated with a high thromboembolic risk. Although warfarin has traditionally been used, direct oral anticoagulants (DOACs) offer a more convenient alternative. With the addition of the RIVAWAR trial, we conducted an updated systematic review and meta-analysis to assess the efficacy and safety of DOACs compared with warfarin in patients with LV thrombus. Methods: A systematic search of electronic databases (PubMed, EMBASE, Cochrane and clinicaltrials.gov) from inception to April 2025 identified randomised clinical trials (RCTs) comparing DOACs with warfarin for the treatment of LV thrombus. The main outcome of interest was thrombus resolution at 3 months. Risk ratios (RRs) with 95% CIs were calculated using random-effects models. Results: Seven RCTs comprising 554 patients were included. Non-contrast transthoracic echocardiography was used for LV thrombus assessment in all RCTs. There was no difference between DOACs and warfarin in thrombus resolution at 3 months (RR 1.02; 95% CI 0.95 to 1.09), major adverse cardiovascular events (RR 0.50; 95% CI 0.16 to 1.54), all-cause mortality (RR 0.92; 95% CI 0.36 to 2.31), stroke/systemic embolism (RR 0.76; 95% CI 0.12 to 4.68), rehospitalisation (RR 1.36; 95% CI 0.47 to 3.94) or major bleeding (RR 0.54; 95% CI 0.20 to 1.48). Subgroup and sensitivity analyses confirmed the robustness of these results. Conclusions: DOACs demonstrated similar efficacy and safety to warfarin for LV thrombus management in this meta-analysis, supporting their use for the treatment of LV thrombus. However, large-scale RCTs with longer follow-up periods and using diagnostic modalities with higher sensitivity and specificity for detecting LV thrombus resolution are warranted to confirm these findings and clarify long-term outcomes. PROSPERO registration number: CRD420251023513.

28 November 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
BCBernardo Gabriele Collaco
Bernardo Gabriele Collaco
RLRaquel Nogueira Cordeiro L Lima
Raquel Nogueira Cordeiro L Lima
PMPedro Lucas Machado Magalhães
Pedro Lucas Machado Magalhães
SHSyed Ali Haider
Syed Ali Haider
GCGabriel Cavalcante Lima Chagas
Gabriel Cavalcante Lima Chagas
AEAdekunle I. Elegbede
Adekunle I. Elegbede

1 April 2026 in Endocrine Practice
Verified
Journal Article
Closed access
BSBruno L. Souza
Bruno L. Souza
JAJessica Abramowitz
Jessica Abramowitz
SMSasan Mirfakhraee
Sasan Mirfakhraee
MTMaria E.C. Tamega
Maria E.C. Tamega
YCYosteline Costa
Yosteline Costa
MAMarconi Abreu
Marconi Abreu

11 May 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
CSCynthia Francisca Xavier Costa de Assis Silva
Cynthia Francisca Xavier Costa de Assis Silva
BSBruno Lins de Souza
Bruno Lins de Souza
GTGianlucca Thomazini
Gianlucca Thomazini
JJJardeson Júnior
Jardeson Júnior
OBOscar de Mendonça Bisneto
Oscar de Mendonça Bisneto
MAMarconi Abreu
Marconi Abreu